CHEK2 and prostate carcinoma: Mutations in the ATM and CHEK2 have been associated with the development of various cancers, including breast cancer, lung cancer, pancreatic cancer, prostate cancer, and colorectal cancer.[62, 63] The presence of ATM and CHEK2 mutations in the metastasis clone suggests potential implications for the metastatic process.